Evidence map›Paper›PMID 35464194›Full record

ArticleFrontiers in chemistry2022

Design, Synthesis, and Antitumor Activity Study of All-Hydrocarbon-Stapled B1-Leu Peptides.

Zhen Su, Chao Liu, Wei Cong, Shipeng He, Li Su, Honggang Hu

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Zhen SuInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Chao LiuInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Wei CongInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Shipeng HeInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Li SuInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Honggang HuInstitute of Translational Medicine, Shanghai University, Shanghai, China.
Shanghai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B1-Leu peptide is a structural optimization compound derived from the lysine- and phenylalanine-rich antimicrobial peptide Cathelicidin-BF. It has shown promising antibacterial and antitumor biological activity. However, linear peptides are not the best choice for novel drug development due to their poor pharmacokinetic properties. In this study, various all-hydrocarbon stapled B1-Leu derivatives were designed and synthesized. Their secondary structure, protease stability, and antitumor and hemolytic activities were also investigated to evaluate their clinical value for cancer therapy. Among them, B1-L-3 and B1-L-6 showed both damaging the tumor cell membrane stability and antitumor activity, showing that they are promising lead compounds for the development of novel cancer therapeutics.

Indexed as

all-hydrocarbon staplingantimicrobial peptides (AMPs)antitumor biological activityB1-leucathelicidin-BF

Identifiers

PMID35464194
PMCPMC9021566
OpenAlexW4225923507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.